{
  "entities": {
    "activities": {
      "7e776f76-7c7a-49fc-86f1-eddb31885ea3": "Bone Marrow Examination",
      "3ee3cc9c-3f4b-4c23-a273-cfacf35f92a0": "Bone marrow aspirate for MRD assessment",
      "776840d4-448f-4be2-bdab-2d7ea9a5c96f": "Bone marrow aspirate for resistance mechanisms",
      "eee077a8-e5d4-4ce3-8b1b-f3fe0ddafa6b": "Clonality of plasma cells (flow cytometry, IHC or IF)",
      "b6348667-4252-4460-83fe-4f3ba026c8a6": "Cytogenetic analysis (karyotype or FISH)",
      "e534c6ee-5c5f-474f-b2b6-5ea5d5ca98d7": "Disease characterization (morphology, IHC, flow cytometry)",
      "658f8f44-0ef1-4c41-a168-b31dca486015": "Electrocardiogram",
      "693f5d3c-0a69-4451-a86c-d4518bc8242f": "Hepatitis B DNA Testing",
      "396acf7d-da40-41c5-be11-1f1b81ec6978": "Imaging for Lytic Disease",
      "deed8bcb-fa98-47f3-ad56-2ac90d33c5ea": "Intravenous Infusion",
      "b7eff2d5-18a8-40d8-a052-48525652e982": "MRD and molecular subtyping",
      "a4da14f5-21ab-45c7-bde2-e8a47c79ea80": "Physical Examination",
      "db1ebacf-dbc1-4363-b00f-313542c56201": "Plasma cell percentage in bone marrow",
      "c5ae7a77-f2dc-41e6-9dc0-b936a00bb5e8": "Subcutaneous Injection",
      "48936ba3-cc85-437e-9b21-311ccae2a33b": "Urine Collection",
      "a49166c8-80ce-4f12-aa2e-526676e1c9e3": "Venipuncture",
      "b6be9b3e-a310-45cf-863c-0e5cc54a5c26": "Vital Signs Monitoring"
    },
    "plannedTimepoints": {},
    "encounters": {
      "b9254e1d-0cc6-440c-b9d4-e58a4bdadd1a": "Treatment (Post C1D1)",
      "d0bd85cf-a45e-4223-a4cb-066596809c3e": "Disease Progression Visit",
      "aa4aa9b4-8373-40ac-a544-dcbdad98fa6e": "Screening (Up to 42 days)",
      "73a29072-a6e5-4178-bb8d-0b6dba83fdd7": "Treatment (Suspected CR/sCR)"
    },
    "epochs": {
      "386cc9ac-f7f8-406e-b6e1-083a58b2d477": "Screening",
      "2748839e-b894-4fe5-a86f-30e46ada3773": "During Treatment",
      "7f15e1f5-4d1e-4490-bb66-8931cea7563e": "Disease Progression"
    },
    "activityGroups": {}
  },
  "cells": {
    "e534c6ee-5c5f-474f-b2b6-5ea5d5ca98d7|aa4aa9b4-8373-40ac-a544-dcbdad98fa6e": "both",
    "b6348667-4252-4460-83fe-4f3ba026c8a6|aa4aa9b4-8373-40ac-a544-dcbdad98fa6e": "both",
    "db1ebacf-dbc1-4363-b00f-313542c56201|73a29072-a6e5-4178-bb8d-0b6dba83fdd7": "both",
    "eee077a8-e5d4-4ce3-8b1b-f3fe0ddafa6b|73a29072-a6e5-4178-bb8d-0b6dba83fdd7": "both",
    "b7eff2d5-18a8-40d8-a052-48525652e982|aa4aa9b4-8373-40ac-a544-dcbdad98fa6e": "both",
    "3ee3cc9c-3f4b-4c23-a273-cfacf35f92a0|73a29072-a6e5-4178-bb8d-0b6dba83fdd7": "both",
    "3ee3cc9c-3f4b-4c23-a273-cfacf35f92a0|b9254e1d-0cc6-440c-b9d4-e58a4bdadd1a": "both",
    "776840d4-448f-4be2-bdab-2d7ea9a5c96f|d0bd85cf-a45e-4223-a4cb-066596809c3e": "both"
  },
  "cellFootnotes": {
    "eee077a8-e5d4-4ce3-8b1b-f3fe0ddafa6b|73a29072-a6e5-4178-bb8d-0b6dba83fdd7": [
      "**"
    ],
    "3ee3cc9c-3f4b-4c23-a273-cfacf35f92a0|73a29072-a6e5-4178-bb8d-0b6dba83fdd7": [
      "*"
    ],
    "3ee3cc9c-3f4b-4c23-a273-cfacf35f92a0|b9254e1d-0cc6-440c-b9d4-e58a4bdadd1a": [
      "*"
    ]
  },
  "metadata": {
    "model": "gemini-3-flash-preview",
    "extraction_type": "text"
  }
}